Cargando…
Structural determinants of dual incretin receptor agonism by tirzepatide
Tirzepatide (LY3298176) is a fatty-acid-modified, dual incretin receptor agonist that exhibits pharmacology similar to native GIP at the glucose-dependent insulinotropic polypeptide receptor (GIPR) but shows bias toward cyclic adenosine monophosphate signaling at the glucagon-like peptide-1 receptor...
Autores principales: | Sun, Bingfa, Willard, Francis S., Feng, Dan, Alsina-Fernandez, Jorge, Chen, Qi, Vieth, Michal, Ho, Joseph D., Showalter, Aaron D., Stutsman, Cynthia, Ding, Liyun, Suter, Todd M., Dunbar, James D., Carpenter, John W., Mohammed, Faiz Ahmad, Aihara, Eitaro, Brown, Robert A., Bueno, Ana B., Emmerson, Paul J., Moyers, Julie S., Kobilka, Tong Sun, Coghlan, Matthew P., Kobilka, Brian K., Sloop, Kyle W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060465/ https://www.ncbi.nlm.nih.gov/pubmed/35333651 http://dx.doi.org/10.1073/pnas.2116506119 |
Ejemplares similares
-
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020) -
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
por: Kawai, Takahiro, et al.
Publicado: (2020) -
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023) -
Structural basis for GPR40 allosteric agonism and incretin stimulation
por: Ho, Joseph D., et al.
Publicado: (2018) -
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
por: Samms, Ricardo J., et al.
Publicado: (2022)